Comparative Pharmacology
Head-to-head clinical analysis: ARMODAFINIL versus DEXAMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMODAFINIL versus DEXAMPEX.
ARMODAFINIL vs DEXAMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armodafinil is a wakefulness-promoting agent. Its mechanism is unclear but may involve inhibition of dopamine reuptake, leading to increased extracellular dopamine levels. It also affects orexin, histamine, norepinephrine, and GABA pathways.
Dextroamphetamine is a central nervous system stimulant that increases extracellular dopamine and norepinephrine levels by blocking their reuptake and promoting release from presynaptic terminals.
Adults: 150-250 mg orally once daily in the morning for narcolepsy or obstructive sleep apnea; 200-400 mg orally once daily for shift work disorder.
5-10 mg orally once daily in the morning, maximum 20 mg/day.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Cyclosporine
"The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil."
Clinical Note
moderateArmodafinil + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
Clinical Note
moderateCyclophosphamide + Armodafinil
12–15 hours (terminal) in adults; longer in hepatic impairment (e.g., 20–30% increase with cirrhosis).
Terminal elimination half-life 10–13 hours in adults (7–8 hours in children). Longer in alkaline urine (up to 20 hours) due to reduced renal tubular reabsorption.
Renal: ~80% as metabolites (major: armodafinil acid, minor: modafinil sulfone); fecal: <1% unchanged; biliary: negligible.
Renal: ~90% as unchanged drug and metabolites (primarily deaminated metabolites); fecal/biliary <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Armodafinil can be decreased when combined with Cyclophosphamide."